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Objective: Antispastic protocols for arterial grafts are important in arterial grafting for
coronary artery bypass grafting surgery. We designed a new nicardipine and nitro-
glycerin cocktail that is composed of a second-generation dihydropyridine calcium
antagonist, nicardipine and nitroglycerin (30 mmol/L), and examined its effect in hu-
man internal thoracic and radial arteries.
Methods: Human internal thoracic (n5 86) and radial (n5 74) artery segments from
72 patients undergoing coronary artery bypass grafting were studied. Relaxation
against 3 classic vasoconstrictors (potassium chloride, thromboxane A2 mimetic
U46619, and a-adrenoceptor agonist norepinephrine) and prophylactic effect on con-
traction against these vasoconstrictors were examined. The effect of the nicardipine
and nitroglycerin cocktail on the endothelial function in internal thoracic and radial
arteries was studied in response to acetylcholine.
Results: Nicardipine and nitroglycerin induced almost full relaxation (92.2%6 4.7%
to 97.9%6 1.0%, P, .001 in internal thoracic arteries and 95.4%6 1.9% to 96.7%
6 3.3%, P , .001 in radial arteries, n 5 6–8) against 3 vasoconstrictors with sig-
nificant prophylactic effect on contraction (maximal contraction was depressed to
32.5% to 76.4%, P , .05 or P , .001, and EC50s were increased to 5 to 42-fold
more, P , .01). After treatment with the nicardipine and nitroglycerin cocktail, the
acetylcholine-induced relaxation was unchanged (P . .05).
Conclusion: The use of the nicardipine and nitroglycerin cocktail provides a new anti-
spastic protocol that has rapid onset, full relaxation, and excellent prophylactic effect
against all known mechanisms of vasospasm and maximally protects the endothelial
and smooth muscle function of the internal thoracic and radial arteries. The cocktail is
therefore expected to provide a new method in treating grafts in coronary artery
bypass grafting with the best antispastic effect and protection of the graft.
T
he antispastic protocol for arterial grafts is important in arterial grafting for cor-
onary artery bypass grafting (CABG) to maximally reduce vasospasm-related
complications.1-4 The prevention or relief of vasospasm in arterial grafts not
only solves the vasospastic problem that reduces the perioperative graft spasm and
complications related to it but also plays a role in the long-term patency because of
the protective effect of the solution on the endothelium that is related to less surgical
manipulation when the artery is relaxed.3,5
The antispastic protocol has been evolving since the 1980s. A number of protocols
have been recommended.6-27 In general, choosing a particular protocol depends on the
availability of drugs and the preference of the surgeon. An ideal protocol should take
into account the following. First, the drugs have to be effective in both relieving and
preventing vasospasm. The former refers to the relaxing effect when the vessel is con-
tracted, and the latter refers to preventing contraction by using the drug(s) beforehand.
Second, such a protocol should be able to protect the vascular endothelium as much as
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CDAbbreviations and Acronyms
Ach 5 acetylcholine
CABG 5 coronary artery bypass grafting
ITA 5 internal thoracic artery
K1 5 potassium chloride
NE 5 norepinephrine
NG 5 nicardipine and nitroglycerin
NO 5 nitric oxide
NTG 5 nitroglycerin
RA 5 radial artery
SE 5 standard error
VG 5 verapamil and nitroglycerin
possible because intact endothelium is a key structure in the
prevention of platelet aggregation, thrombosis, intima prolif-
eration, atherosclerosis, and the eventual occlusion of the
vessel. Third, the relaxing effect, blockage of the relevant
contractile receptors, and membrane potential changes
should be temporary, lasting only during the perioperative
period. The benefit of an arterial graft is that it is a living
vessel, a ‘‘living conduit,’’ with most receptor properties pre-
served, not a ‘‘dead fibrotic conduit.’’ This means that the
vessel should be able to contract and relax under various con-
ditions. The contraction and relaxation actions are essential
for every small to medium-sized artery in maintaining normal
function. The rhythmic motion keeps the artery a living con-
duit that may be protected from intimal proliferation and ath-
erosclerosis, and therefore will have a superior long-term
patency. The best preservation of a vessel is to maintain it
at physiologic condition with normal receptor properties.
Finally, the ideal protocol should be ecumenically accept-
able; this is particularly important in current health systems
in many countries, particularly in developing countries.
We previously invented a VG (verapamil and nitroglyc-
erin) solution composed of a calcium antagonist, verapamil,
and a nitric oxide (NO) donor, glyceryl trinitrate (nitroglycerin
[NTG]), for use in both arterial and venous grafting. Because
verapamil is not available in all places and its bradycardia ef-
fect may prevent the simultaneous use of a beta-blocker, and
because new generations of calcium antagonists have been de-
veloped, we designed the present study to investigate a new
cocktail that is composed of a second-generation dihydropyr-
idine calcium antagonist: nicardipine and NTG (NG). We
tested this cocktail with regard to the above aspects and report
the excellent effect of this solution on both human internal tho-
racic arteries (ITAs) and radial arteries (RAs).
Materials and Methods
General
Human ITA (n 5 86) and RA (n 5 74) segments were collected
from 72 patients (58 men and 14 women with a mean age of 64.2
6 0.8 years) undergoing CABG using these grafts. Approval to
use discarded RA tissue was given by the institutional review board674 The Journal of Thoracic and Cardiovascular Surgery c Sepat St Vincent Hospital, Portland, Oregon. The surgeon or assistant
received consent from each patient before the operation. The details
of the method to collect and dissect the human arteries were previ-
ously described.1,11 The arteries were cut into 3-mm–long rings and
suspended on wires in organ baths.1,11
Organ-Bath Technique
A specially designed organ-bath technique was used for this study.
The details of the technique have been published.3,28 Briefly, each
arterial ring was stretched up in progressive steps to determine the
individual length-tension curve. A computer iterative fitting
program (VESTAND 2.1, Yang-Hui He, Princeton University,
NJ) was used to determine the exponential line, pressure, and in-
ternal diameter. When the transmural pressure on the rings reached
100 mm Hg, determined from their own length-tension curves, the
stretch-up procedure was stopped and the rings were released to
90% of their internal circumference at 100 mm Hg. This degree of
passive tension was then maintained throughout the experiment.
Because of the importance of endothelium on vascular tone, we
intentionally preserved the endothelium by cautiously dissecting
and mounting the rings.29,30
Protocol
Effects of Nicardipine and Nitroglycerin Solution
The effect of the NG solution was tested in 2 ways as follows.
Relaxation effect against 3 classic vasoconstrictors.
These experiments were designed to investigate the effect
of NG solution in relieving vasospasm developed with rela-
tion to depolarization of the cellular membrane potential
(potassium chloride [K1]), thromboxane A2 (U46619), and
a-adrenoceptors (norepinephrine [NE]).
After the normalization procedure, the vascular rings were
equilibrated for at least 1 hour. One of the 3 vasoconstrictors
(K1 75 mmol/L, U46619 10 nM, or NE 10 mmol/L) was added
to the organ bath. After the contraction reached a stable level,
30 mmol/L nicardipine and 30 mmol/L NTG were added. The
relaxation time course was recorded. The force during relax-
ation was measured at 1-minute intervals and expressed as
a percentage of the force during precontraction.
Prophylactic effect on contraction against three classic
vasoconstrictors. To investigate the prophylactic effect of
NG solution on contraction induced by 3 classic vasocon-
strictors, 2 ITA or RA segments were taken from the same ar-
tery and allocated into 2 groups. One was used as control, and
the other was used for pretreatment with NG solution. After
equilibration for at least 60 minutes, the ITA (n 5 8) or RA
(n 5 7) rings were treated with 30 mM NG for 30 minutes.
Cumulative concentration-contraction curves were then
established for K1 (5–100 mmol/L), U46619 (210 log M to
26.5 log M), and NE (28.5 to 25 log M).
Effect of Nicardipine and Nitroglycerin Solution on
the Endothelial Function in Internal Thoracic and
Radial Arteries
A clinically usable solution must have no harmful effect on
the endothelium. We therefore tested the effect of NGtember 2008
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RA rings taken from the same patient were allocated into 2
groups. One was treated with NG solution for 30 minutes,
and the other was used as control. The rings were normalized
as mentioned above and then equilibrated for 60 minutes.
Precontraction of the rings was induced by U46619. Cu-
mulative concentration-relaxation curves to acetylcholine
(ACh) (210 to 26.5 log M) were established. At the maxi-
mal relaxation to ACh, 30 mM NTG was added if ACh did
not induce full relaxation to demonstrate the integrity of the
relaxing property.
Design of the Nicardipine and Nitroglycerin Cocktail
In the above protocol, we tested the effect of NG at a con-
centration of 30 mmol/L (24.5 log M) on the human ITA
and RA segments in the organ chamber. From previous stud-
ies,8,11,17,31 this concentration was expected to have maximal
or nearly maximal effect.
Nicardipine and Nitroglycerin Cocktail
The components of the clinical (NG) cocktail are as follows:
Nicardipine hydrochloride 5 mg
NTG 5 mg
8.4% NaHCO3 0.3 mL*
Normosol-R solution 300 ml
This cocktail gives a concentration of approximately
30 mmol/L (24.5 log M) of nicardipine or 60 mmol/L
(24.3 log M) NTG in an isotonic solution of pH 7.1.
*The pH of NG (nicardipine hydrochloride 5 mg and NTG
5 mg) in Normosol-R solution (300 mL) without adding
NaHCO3 is 6.6. When the amount of 8.4% NaHCO3 added
is more than 0.3 mL, the solution becomes gradually turbid
until pH 5 7.4 with 8.4% NaHCO3 0.5 mL added. This,
however, does not affect the antispastic effect as seen in the
results of the present study because the effect of NG solution
at the concentration of 30 mmol/L (24.5 log M) was tested in
the organ bath with a pH of 7.4 and slightly turbid-looking.
Onset of Nicardipine and Nitroglycerin Solution
A clinically useful solution for treating arterial grafts should
have a rapid onset to relieve vasospasm as quickly as possible.
To test the onset of the NG solution, we recorded the relaxa-
tion in 1-minute time intervals against all 3 vasoconstrictors.
Data Analysis
The relaxation of ITA and RA was expressed as a percentage
of the vasoconstrictor-induced precontraction. The effective
concentration of the constrictor (or dilator) agent that caused
50% of maximal contraction (or relaxation) was defined as
EC50. The detailed methods have been published.
1,28
All values were expressed as mean 6 standard error.
Statistical comparisons of cumulative contraction force and
cumulative percentage of relaxation were performed by
2-way analysis of variance followed by Bonferroni’s test.The Journal of ThorUnpaired t test or analysis of variance was used to test the
statistical significance among different constrictors and dila-
tors regarding EC50.
Materials
U46619 was a product of the Cayman Chemical Company
(Ann Arbor, Mich). K1, nicardipine hydrochloride, and
L-(-)-norepinephrine(1)-bitartrate salt monohydrate were
purchased from Sigma-Aldrich Chemical Co (St Louis,
Mo). NTG (50 mg/10 mL) was a product of Laboratories
Inc. New York ACh was purchased from Sigma-Aldrich
Chemical Co. Stock solutions of different concentrations of
U46619 and ACh were kept frozen until required. Other re-
agents were regular chemical reagents from Sigma Chemical
Co and stored at room temperature.
Results
Resting Parameters of Internal Thoracic and Radial
Arteries
The internal diameter of the vessels at an equivalent transmu-
ral pressure of 100 mm Hg (D100), determined from the
normalization procedure, was 2.6 6 0.8 mm in ITA and
2.9 6 0.6 mm in RA segments. The transmural pressure
90% of D100 was 76.3 6 0.6 mm Hg in ITA and 76.0 6
0.5 mm Hg in RA (P 5 .8) segments. The resting force
was 3.0 6 0.1 g in ITA and 1.9 6 0.1 g in RA (P , .001)
segments.
Contraction Force in Internal Thoracic and Radial
Arteries
In ITAs, the precontraction force was 1.1 6 0.03 g to K1,
5.7 6 0.4 g to U46619 (P , .001 vs K
1), and 2.0 6 0.3 to
NE (P . .05 vs K1, P , .001, vs U46619). In RAs, the pre-
contraction force was 1.2 6 0.07 g to K1, 7.5 6 0.9 g to
U46619 (P , .001, vs K
1), and 1.8 6 0.2 to NE (P . .05
vs K1 and P , .001 vs U46619).
Effects of Nicardipine and Nitroglycerin Solution
Relaxation effect against 3 classic vasoconstrictors. NG
at a concentration of 30 mmol/L caused almost full (.90%)
relaxation in ITA rings precontracted with 10 nM U46619
(92.2% 6 4.7%, n 5 8), 70 mmol/L K1 (93.9% 6 2.6%,
n 5 8), and 10 mM NE (97.9% 6 1.0%, n 5 8) (P . .05)
(Figure 1, A).
NG at a concentration of 30 mmol/L induced almost full
relaxation in RA rings (95.4%6 1.9% of U46619 precontrac-
tion, 96.7%6 3.3% of K1 precontraction, and 95.8%6 1.6%
of NE precontraction; n 5 6 in each group) (Figure 1, B).
Onset of Nicardipine and Nitroglycerin Solution
The NG solution has a rapid onset of relaxation against all 3
vasoconstrictors, as shown in Figure 2. At 5 minutes, the
relaxation reached 60.8% 6 6.5% against U46619, 55.6%
6 6.1% against K, and 92.6% 6 3.0% against NE in theacic and Cardiovascular Surgery c Volume 136, Number 3 675
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Figure 1. Percentage of relaxation in-
duced by nicardipine (30 mmol/L) and
glycerol trinitrate (nitroglycerin, NTG
30 mmol/L) in ITA (A, n 5 8) and RA (B,
n 5 6) rings precontracted by U46619 (10
nM), K1 (70 mmol/L), or NE (10 mM).
Values are expressed as mean 6 stan-
dard error (SE). P> .05 (one-way analy-
sis of variance followed by Bonferroni's
multiple comparison test). ITA, Internal
thoracic artery; RA, radial artery; NE,
norepinephrine; K1, potassium chloride.ITA rings. Similarly, the relaxation reached 64.4% 6 7.3%
against U46619, 63.4% 6 6.3% against K, and 75.1% 6
14.6% against NE in the RA rings. At 20 minutes, the relax-
ation reached submaximal (77%–96% in ITA rings and
76%–86% in RA rings) and lasted to the end of experiment
(.120 minutes, Figure 2).
Prophylactic Effect on Contraction Against Three
Classic Vasoconstrictors (Depression of Contraction
by Pretreatment with Nicardipine and Nitroglycerin)
Pretreatment with 30 mmol/L NG for 30 minutes significantly
depressed the magnitude of the contraction induced by
U46619 (Figure 3), K
1 (Figure 4), and NE (Figure 5) in
both human ITA (Figures 3–5, A) and RA rings (Figures
3–5, B).
Pretreatment of ITA and RA with NG also significantly
desensitized the vessel to the 3 classic vasoconstrictors.
The EC50 values for U46619-contracted ITA and RA rings in-
cubated with NG were 7-fold (P, .001) and 5-fold (P, .01)
higher than that of control. In addition, EC50 values of K
1
were 6-fold (P, .01) higher than that of control in RA rings
and 42-fold (P, .001) higher than that of NE in ITA rings. In
addition, the maximal contraction force in treated groups was
76.4% (P, .05), 52.5% (P, .001), and 32.5% (P5 .001) of
the corresponding control in U46619, K
1, and NE-contracted
ITA rings and 69.2% (P, .01), 40.3% (P, .05), and 15.6%
(P , .001) in RA rings.676 The Journal of Thoracic and Cardiovascular Surgery c SepEffect of Nicardipine and Nitroglycerin Solution on
the Endothelial Function in Internal Thoracic and
Radial Arteries
Cumulative concentration-relaxation curves for ACh were
established in U46619-contracted ITA and RA rings incubated
with or without 30 mmol/L NG (Figure E1.). There were no
significant differences with regard to the maximal relaxation
or the EC50 in ITAs or RAs (27.536 0.58 vs27.196 0.07
log M in ITAs and27.936 0.88 vs27.686 0.29 log M in
RAs, P . .05).
Discussion
The major findings of this study are as follows: 1) The
combination of a second-generation dihydropyridine and
NO donor (NTG) can be used for relieving vasospasm in
the arterial grafts (both ITA and RA) in CABG. 2) This
cocktail may also prevent vasospasm related to a number of
vasoconstrictors, including depolarizing mechanism, throm-
boxane A2, and a-adrenoceptor–mediated vasospasm. 3)
The cocktail maximally protects endothelial function in the
arterial grafts.
Vasospasm Problems in Arterial Grafting
From both theoretic and practical aspects, arterial grafting is
better than venous grafting. In fact, the patency rates of sa-
phenous vein grafts in the early reports were unsatisfactory.
The occlusion rate of saphenous vein grafts in the first year0
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Figure 2. Onset and time course of the
relaxation induced by nicardipine
(30 mmol/L) and glycerol trinitrate
(nitroglycerin, NTG, 30 mmol/L) in ITA
(A, n 5 8) and RA (B, n 5 6) rings pre-
contracted by U46619 (10 nM), K
1 (70
mmol/L), or NE (10 mM). Values are ex-
pressed as mean 6 SE. Note that in
the first 20 minutes, relaxation reached
almost the maximal in both ITA and RA
rings. NE, Norepinephrine; K1, potas-
sium chloride.tember 2008
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Figure 3. Mean concentration-contrac-
tion (g) curves for U46619 (210 to 26.5
log M) in ITA (A, n 5 8) and RA (B, n 5
7) rings pretreated with or without (con-
trol) treatment of NG (nicardipine 30
mmol/L; NTG 30 mmol/L) for 30 minutes.
Values are expressed as mean 6 SE.
**P < .01, ***P < .001, compared with
control. NG, Nicardipine and nitroglyc-
erin.A
CDis 10% to 26%.32-34 By 10 years, 50% of the grafts are
occluded35,36 and of the grafts still patent, 50% show marked
atherosclerotic changes.34 Although compared with 30 years
ago, the patency of saphenous vein grafts has improved to
78% at 5 years, 60% at 10 years, and 50% at 15 years because
of advances in venous grafting techniques,37 it is still not
comparable to arterial grafting. As a result, arterial grafting
has been popular since the 1980s, and ITAs and RAs are
most frequently used now.4,36,37 On the other hand, because
of the tendency of vasospasm development in arterial grafts
that may cause mortality or morbidity, antispastic protocols
became essential for arterial grafting. For ITAs, the use of
vasodilator drugs is a routine practice.6,7,9,10,12,13,18,19,25,26
For RAs, it was the use of calcium antagonists that made
the revival of this graft after the initial abandonment,4 and
a number of antispastic protocols have been recommended
for RA grafting ever since.11,16,17,20,21-24,27 However, as to
the best antispastic protocol, there is no unanimous opinion
because of the variable availability of vasodilator drugs at dif-
ferent locations and the surgeon’s preference. Further, the
pharmaceutical development may also become a factor in
the evolution of the antispastic protocol.
Cause of Vasospasm: Various Vasoconstrictors
We have systemically investigated the effect of various vaso-
dilator drugs on arterial grafts regarding both the vasodilatory
effect in established vasoconstriction and the prophylacticThe Journal of Thoeffect on vasoconstriction. These studies indicated that there
is no single vasodilator drug that is effective against all vaso-
constrictors.1,28,30,37-42 This is because the real cause of vaso-
spasm—the extreme form of vasoconstriction—is unknown,
although it may be related to a number of causes.
In general, vasospasm could be the response of a vessel to
many stimulants.40 These stimulants may be physical (eg,
mechanical stimulation or temperature changes) or phar-
macologic (eg, nerve stimulation or vasoconstrictor sub-
stances). Exogenous and endogenous vasoconstrictors are
particularly important for vasoconstriction and its extreme
form, vasospasm.
There are many vasoconstrictor substances that are related
to vasospasm, as we outlined previously.40 In addition, argi-
nine vasopressin is also a spasmogen for grafts.42 When
vasospasm occurs, it is often unknown which of the above
vasoconstrictors is involved and to what degree. The interac-
tion among the vasoconstrictors may also play a role in the
mechanism of vasospasm.
In view of the complexity of the mechanism of vasospasm
mentioned above, it is difficult to choose the ‘‘best’’ method
to solve (relief or prevent) vasospasm. However, it is most
likely that vasodilator substance(s) that are effective against
all the above mechanisms would be the most reliable clinical
method. a-adrenoceptor antagonists (eg, phentolamine and
phenoxybenzamine) are only effective against a-adrenocep-
tor agonists but ineffective to any other receptor-mediated0
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Figure 4. Mean concentration-contrac-
tion (g) curves for K1 (5–100 mmol/L) in
ITA (A, n 5 8) and RA (B, n 5 7) rings
pretreated with or without (control)
treatment of NG (nicardipine 30 mmol/
L; NTG 30mmol/L) for 30 minutes. Values
are expressed as mean6 SE. **P< .01,
***P < .001, compared with control.
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Figure 5. Mean concentration- (mmol/L)
contraction (g) curves for NE (28.5 to25
log M) in (A) ITA (n5 8) and (B) RA (n5
7) rings pretreated with or without (con-
trol) treatment of NG (nicardipine 30
mmol/L; NTG 30 mmol/L) for 30 minutes.
Values are expressed as mean 6 SE.
**P < .01, ***P < .001, compared with
control. NG, Nicardipine and nitroglyc-
erin.(eg, thromboxane A2) or membrane depolarization-mediated
(eg, K1) contraction. Similarly, calcium antagonists are
particularly effective in reversing or preventing membrane
potential depolarizing agent potassium ion-mediated contrac-
tion. This is because calcium antagonists particularly inhibit
voltage-dependent calcium channels, but they are relatively
ineffective in a-adrenoceptor38 or other receptors, such as
thromboxane A2-mediated contraction. With regard to the
clinically useful NO donor NTG and nitroprusside, they are
particularly effective in reversing the contraction mediated
by a number of receptor-mediated vasoconstrictors, such as
a-adrenoceptor,1,43 thromboxane A2,1 angiotensin-II,44 and
the K1-mediated contraction. Further, we have demonstrated
that vasodilators that are effective in relaxing contracted ves-
sels may not be as effective in preventing vasoconstriction.
This is particularly true for the NO donor NTG.1 In contrast,
calcium antagonists (including nicardipine) are particularly
effective in preventing K1-mediated contraction in both the
ITA1 and RA.31 These observations led us to believe that
a combination of vasodilator drugs would be the best choice
to prevent or relieve vasospasm.3,8,11,29 We previously devel-
oped a cocktail composed of verapamil and NTG that has
been demonstrated to be effective against all the above mech-
anisms. We demonstrated that among the 3 most important
calcium antagonists, dihydropyridine nifedipine was the
most potent. However, during that time (1980s), there were
no intravenous dihydropyridine preparations available; there-
fore, verapamil was chosen for the cocktail because it was the
next potent calcium antagonist. Verapamil had a good relax-
ation effect, better than diltiazem, and it was available as an
intravenous preparation. The topical and intraluminal uses of
VG solution have been proved effective in arterial graft-
ing,3,8,11 and even intracoronary artery injection through
catheterization was reported by us17 and others.45,46 How-
ever, verapamil has a bradycardia effect, particularly when
beta-blockers are used, and therefore simultaneous systemic
use of verapamil and beta-blockers is usually contraindi-
cated. Instead, nicardipine, as the second generation of dihy-
dropyridine calcium antagonist, is used frequently during
CABG for intravenous dripping as an antispastic protocol678 The Journal of Thoracic and Cardiovascular Surgery c Septfor arterial grafting.22 We previously demonstrated that ni-
cardipine has a satisfactory relaxation effect on arterial grafts
such as ITA and RA against depolarizing mechanisms.31,47
We therefore designed the present study to develop a new
cocktail for an antispastic protocol.
The present study investigated the effect of this cocktail
solution on the 2 major arterial grafts: ITA and RA. We there-
fore have good reason to believe that this cocktail would
provide excellent antispastic effect in clinical use for arterial
grafting. The solution is designed mainly for topical spray or
intraluminal injection into arterial grafts because it is made of
intravenous injection preparations, as we previously used for
VG solution. In fact, the VG solution was used by others in
catheterization for either coronary artery45 or neuroendovas-
cular surgery.46 We anticipate that this new NG cocktail can
also be used for these purposes. Figure E2 illustrates the anti-
spastic mechanism of the NG cocktail that is effective against
known vasoconstrictors.
Integrity of Function of Endothelium and Smooth
Muscle
The key role of endothelium in maintaining vascular tone and
preventing atherosclerosis has been well documented. Our
results have clearly shown that the NG solution has no
adverse effect on endothelium; in other words, the endothe-
lium of ITAs and RAs is well preserved by the NG solution,
demonstrated by normal endothelium-dependent relaxation
to ACh after treatment with NG for more than 30 minutes
(Figure E1).
Further, dihydropyridine derivatives have been de-
monstrated to relax blood vessels through endothelium-
dependent mechanisms by increasing endothelial nitric oxide
synthase expression in the endothelial cell, in addition to its
calcium antagonism mechanism in the smooth muscle.48
Therefore, the use of dihydropyridine derivatives may
provide an additional benefit in the protection of endothe-
lium-smooth muscle function in the grafts.
A common idea in antispastic protocols in CABG is to
make the grafts fully relaxed with the expectation of no con-
traction at all. The ideal is that this may make the graftember 2008
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coronary system. A typical example of this kind of antispastic
protocol is using phenoxybenzamine,21 which is a ‘‘perma-
nent’’ inhibitor of a-adrenoceptor, meaning that once phe-
noxybenzamine is used, the a-adrenoceptor of the vessel is
permanently deactivated. However, there are 2 concerns
about this concept. First, as expected, the specific a-adreno-
ceptor inhibitor phenoxybenzamine has little or no effect
against all other vasoconstrictors, as mentioned before.
Second, we believe that in CABG, a graft should have its in-
tegrity regarding its receptors allocated in both endothelium
and smooth muscle. A well-functioning graft should be
able to relax and contract; it is the balance between contrac-
tion and relaxation that maintains the graft as a ‘‘living con-
duit.’’ The normal contraction and relaxation of a vessel is
a basic physiologic requirement to maintain its function.
For example, when the saphenous vein graft is prepared by
distention under high pressure, the structure of the wall of
the vein is destroyed and the vein becomes a ‘‘dead conduit,’’
which is the major reason for the low patency of the venous
graft. We therefore designed our antispastic protocols to
maximally maintain the integrity of the vessel, both the endo-
thelium and smooth muscle. The new NG cocktail fulfills this
requirement because it maximally protects the endothelium
and the receptors of the smooth muscle.
Conclusions
The use of second-generation dihydropyridine, nicardipine
and NO donor NTG cocktail, provides a new antispastic
protocol that has a rapid onset, full relaxation, and an excel-
lent prophylactic effect against all known mechanisms of
vasospasm and maximally protects the endothelial and
smooth muscle function of the ITA and RA. The cocktail
is therefore expected to provide a new method in treating
grafts during CABG with the best antispastic effect and pro-
tection of the graft.
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Figure E1. Mean concentration- (logM)
relaxation (%) curves for ACh (210 to
26.5 log M) in U46619-contracted ITA
(A, n 5 6) and RA (B, n 5 8) rings pre-
treated with or without NG (nicardipine
30 mmol/L; NTG 30 mmol/L) for 30 min-
utes. Values are expressed as mean 6
SE. P > .05, compared with control
(2-way analysis of variance followed
by Bonferroni tests). NG, Nicardipine
and nitroglycerin.A
CD
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CDFigure E2. Schema showing the mechanism of the antispastic ef-
fect of NG cocktail. Nicardipine, as a calcium channel blocker, is
particularly effective against the mechanism of vasoconstriction
through membrane depolarization that is voltage-dependent31
but less effective in receptor-mediated mechanisms. In contrast,
NTG, as an NO donor, is effective in all mechanisms and particu-
larly effective in receptor-mediated mechanisms.1 NG, Nicardi-
pine and nitroglycerin; NTG, nitroglycerin; PGF2a, prostaglandin
F2a; 5-HT, 5-hydroxytryptamine.680.e2 The Journal of Thoracic and Cardiovascular Surgery c September 2008
